• Home
  • Metro Asian News
  • Misc Asia
  • Lifestyle
  • Business
  • Art
  • Health
  • Sports
  • Eat Out
  • Classified
  • PODCAST
    • Apa Kabar Indonesia
    • Atlanta Burmese Voice
    • SungKhom Lao
    • Usapang Pinoy
ABOUT
Advertise in GAT
Contact us
Sunday, June 26, 2022
Georgia Asian Times
International Insurance of Georgia
  • Home
  • Metro Asian News
  • Misc Asia
  • Lifestyle
  • Business
  • Art
  • Health
  • Sports
  • Eat Out
  • Classified
  • PODCAST
    • Apa Kabar Indonesia
    • Atlanta Burmese Voice
    • SungKhom Lao
    • Usapang Pinoy
No Result
View All Result
  • Home
  • Metro Asian News
  • Misc Asia
  • Lifestyle
  • Business
  • Art
  • Health
  • Sports
  • Eat Out
  • Classified
  • PODCAST
    • Apa Kabar Indonesia
    • Atlanta Burmese Voice
    • SungKhom Lao
    • Usapang Pinoy
No Result
View All Result
Georgia Asian Times
No Result
View All Result
  • Home
  • Metro Asian News
  • Misc Asia
  • Lifestyle
  • Business
  • Art
  • Health
  • Sports
  • Eat Out
  • Classified
  • PODCAST
Home Feature

Johnson & Johnson’s one-shot COVID-19 vaccine effective and safe: FDA staff

Georgia Asian Times by Georgia Asian Times
February 24, 2021
in Feature, Health

Glass Medicine Vials and hualuronic collagen and flu syringe. Tinted image.

Share on FacebookShare on Twitter

Washington DC, Feb 24, 2021 – Johnson & Johnson’s one-shot COVID-19 vaccine appeared safe and effective in trials, U.S. Food and Drug Administration (FDA) staff said in documents published on Wednesday, paving the way for its approval for emergency use.

The FDA’s panel of independent experts meets on Friday to decide whether to approve the shot. While it is not bound to follow the advice of its experts, the FDA usually does and has authorized vaccines from Pfizer and Moderna.

J&J said in documents submitted to the FDA that its data suggested its vaccine was effective at preventing asymptomatic infections. It said that in a preliminary analysis of its trial, it found 16 cases of asymptomatic cases in the placebo group versus two in the vaccine group, or an 88% efficacy rate.

While asymptomatic infection was not the primary goal of the trial, which studied the vaccine’s ability to stop moderate to severe COVID-19, the reduction of asymptomatic cases implies the shot can also cut transmission of the disease.

AD: High Museum of Atlanta

J&J’s vaccine was 66% effective in preventing COVID-19 against multiple variants in a global trial involving nearly 44,000 people, the company said last month.

Its effectiveness varied from 72% in the United States to 66% in Latin America and 57% in South Africa, where a new variant has spread, though the vaccine was 85% effective overall in stopping severe cases of the disease.

The vaccine was effective in reducing the risk of COVID-19 and preventing PCR-test confirmed COVID-19 at least 14 days after vaccination, the FDA said in its briefing documents.

Fourteen days after injection, only two vaccine recipients developed COVID-19 severe enough to need medical intervention, compared with 14 in the placebo group. After 28 days, no vaccine recipients developed COVID severe enough to require medical intervention whereas seven in the placebo group did.

Three vaccine recipients had severe side effects in the trial that were likely related to the vaccine, but the FDA said its analysis did not raise any specific safety concerns that would preclude issuance of an emergency use authorization.

The FDA said the most common solicited adverse reactions were injection site pain at 48.6%, headache at 39%, fatigue at 38.2% and myalgia at 33.2%. Other side effects included a fever in 9% of participants and a high fever in 0.2% of those who received the vaccine.

The regulator said one case of pericarditis, a heart disease, may have been caused by the vaccine. It said cases of a rare disorder, Guillain-Barre Syndrome, were unlikely to be related to the shot though data was insufficient to determine whether or not the vaccine had caused these side effects.

J&J had not previously released details of its clinical trial data beyond efficacy rates.
– Reuters

Tags: COV19Johnson & Johnsonvaccines
Previous Post

Tiger Woods awake and responsive after crash, police investigating cause

Next Post

U.S. House plans vote on COVID-19 aid bill on Friday

Georgia Asian Times

Georgia Asian Times

Related Posts

FDA authorizes 1st COVID-19 shots for infants, preschoolers
Health

FDA authorizes 1st COVID-19 shots for infants, preschoolers

June 18, 2022
US lifts COVID-19 test requirement for international travel
Health

US lifts COVID-19 test requirement for international travel

June 11, 2022
Health

Moderna says updated COVID shot boosts omicron protection

June 8, 2022
Some cancer patients can skip treatments, 2 studies show
Health

Some cancer patients can skip treatments, 2 studies show

June 7, 2022
Melatonin poisoning reports are up in kids, study says
Health

Melatonin poisoning reports are up in kids, study says

June 3, 2022
Gwinnett County AAPI share experiences with mental health
Health

Gwinnett County AAPI share experiences with mental health

May 23, 2022
Next Post

U.S. House plans vote on COVID-19 aid bill on Friday

Signup Free E-Newsletter

Upcoming Events

Jul 15
6:00 pm - 10:00 pm

GAT 25 Most Influential Asian Americans in Georgia-2022 Awards Gala

Sep 17
September 17 @ 11:00 am - September 18 @ 6:00 pm

JapanFest 2022

View Calendar

 

CONTACT US

Follow Us

MOST INFLUENTIAL

GAT 25 Most influential Asian American in Georgia Awards Gala

2022 GAT 25 Most Influential Asian Americans in Georgia

May 1, 2022
Home

Record turnout at annual GAT 25 Most Influential Asian Americans in Georgia-Awards Gala

July 17, 2021

2021 GAT 25 Most Influential Asian Americans in Georgia

April 30, 2021

LINKS OF INTEREST

ATL Asian Film Festival

GAT on Facebook

  • Contact Us
  • Advertise in GAT
  • ABOUT

© 2022 Georgia Asian Times - empowered by 8SOL

No Result
View All Result
  • Home
  • Metro Asian News
  • Misc Asia
  • Lifestyle
  • Business
  • Art
  • Health
  • Sports
  • Eat Out
  • Classified
  • PODCAST
    • Apa Kabar Indonesia
    • Atlanta Burmese Voice
    • SungKhom Lao
    • Usapang Pinoy

© 2022 Georgia Asian Times - empowered by 8SOL

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist